DrugS

Information from Merck announcing a new indication linked below.

Click to Download.

For prescribers: please click here for state-required price disclosures.

On January 27, 2023, the National Comprehensive Cancer Network® (NCCN®) revised its guidelines—now ribociclib (KISQALI®) is the only CDK4/6 inhibitor in combination with an AI designated as a Category 1 Preferred regimen in first-line HR+/HER2- mBC.1,2

Can we set up some time to further explore this major update and review the data that made the NCCN differentiate ribociclib (KISQALI) for first-line use in combination with an AI? Please feel free to contact me at (802) 735-7859 or via email. 

See the evidence that drove the update

Click here to read the NCCN Guidelines®.

Click here for full Prescribing Information for KISQALI.

Lilly USA, LLC is pleased to announce recent major label changes for Retevmo^® (selpercatinib, 80 mg and 40 mg capsules). Read press release here. 

NCCN GUIDELINES^®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Read More. 

Learn more about TRODELVY.  Please click to see full Prescribing Information. 

The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes. With this information, they are equipped to have more informed conversations with their health care providers and be active decision-makers in their long-term health. Read More. 

The NCCN released new Kidney Cancer guidelines (v1.2023) on June 17th and has elevated Fotivda (tivozanib) to be the only Category 1 recommended regimen, for patients that have failed 2 or more systemic treatments.  More Information.  Full Prescribing Information. 

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.  Read More.

Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma.  Read More.

Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information.

Updated Product Ordering Information:

DESCRIPTION	STRENGTH/SIZE	NEW NDC#
TIBSOVO® (ivosidenib tablets)	250 mg tablet   60 tablets/bottle	10 Digit # 72694-617-60  (11 Digit # for ordering 72694-0617-60)

*Per the TIBSOVO® label, the NDC code is 10 digits. We are supplying the 11-digit code for ordering convenience.

The ordering process for TIBSOVO® remains the same.

For full prescribing information regarding TIBSOVO®, please visit www.tibsovo.com.

Servier understands the importance of supplying product to our patients and are committed to ensuring there will be no interruption in supply. We look forward to working with you.

The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system. Read More.